

Cortical and Physiological Modulations Induced by Non-Invasive Brain Stimulation for Anxiety

Faerman, M. V.¹; Smith, A.L.²; Staines, W.R.¹

Department of Kinesiology, Faculty of Health, University of Waterloo, Waterloo, Ontario, Canada¹
Rogee Life Canada Inc., Toronto, Ontario, Canada²



Introduction:

In 2019, 301 million people worldwide were diagnosed with an anxiety disorder. Following the pandemic, the prevalence rate of anxiety increased by 25.6%, that's an addition of 76.2 million anxiety disorder cases globally¹.

Since anxiety is the most prevalent mental health disorder, prioritizing health care for anxiety patients has become a priority for citizens and governments worldwide. The gold standard treatment for anxiety is medication and/or cognitive behavioural therapy (CBT). These approaches have limitations in terms of side effects, stigma, access, effectiveness, cost, and requirements of time that some cases can lead to treatment discontinuation. In response to the demand for new anxiety treatments, one of the technologies that has yielded encouraging results is non-invasive pulsed brain stimulation (NI-PBS). NI-PBS has been approved as a class II medical device by the FDA for over 40 years, and its safety and efficacy has been well-documented in the clinical literature. NI-PBS is the only wearable technology for the treatment of anxiety at home; however, very few patients are aware that it exists.

Up until now, commercially available NI-PBS devices have been too expensive to access and cumbersome to use. New NI-PBS devices are becoming commercially available, ones that are miniaturized, cost-effective, and discreet enough to use in public. As wearable devices become more ubiquitous, anxiety patients may start to use NI-PBS in lieu of or in conjunction with more standard treatments like medication and CBT. For that reason, it's important to understand the physiological mechanisms underlying NI-PBS for the treatment of anxiety.

The purpose of the current study was to assess if one 30-minute session of NI-PBS, applied to bilateral mastoid processes, modulated physiological biomarkers associated with anxiety and the perception of anxiety intensity in the healthy sub-clinical population.

Non-Invasive Pulsed Brain Stimulation:

Non-invasive pulsed brain stimulation (NI-PBS) is a type of wearable technology FDA approved for the treatment of anxiety. It provides a low-level, pulsed electrical stimulation localized behind the ears, thus stimulating the peripheral nerve in this region. Clinical studies show that using NI-PBS once per day for 20-60 minutes for 6 weeks can reduce anxiety symptoms by up to 50%; however, very few people have heard of NI-PBS because up until now, devices have been too cumbersome and expensive.

Our study uses the first miniaturized NI-PBS device called Rogee to investigate how NI-PBS modulates cortical and physiological biomarkers associated with anxiety. There is very little known about the neurophysiological mechanisms underlying the reduction of anxiety symptoms using NI-PBS. There are a few studies showing that NI-PBS can reduce brain activity within the default mode network (DMN) associated with worry and rumination². It can also modulate EEG oscillations. There is no published data on how NI-PBS affects physiological processes associated with anxiety such as heart rate, heart rate variability, or skin conductance.



Fig. 1: NI-PBS device.

Methods:

- Quantitative, open-label study.
- Included healthy participants with moderate or higher levels of anxiety; specifically, those who scored a 9+ on the GAD-7 questionnaire (N = 32, age = 21.03 ± 3.13 years, age range: 18-31 years; 19 females; 13 males).

Protocol:

- The study involved assessing patterns of neural activity using EEG in addition to physiological measures including heart rate, heart rate variability, skin conductance, and subjective perception of anxiety before and after a single 30-minute NI-PBS stimulation session set to 0.5 Hz to a maximum intensity of 500 μ A, with electrodes positioned on bilateral mastoid processes.
- Each participant came to the laboratory once. The experiment contained three phases: Pre-Intervention, Intervention, Post-Intervention (see Figure 2).

- Scalp electroencephalography (EEG) were recorded from a 64-channel EEG cap using the international 10-20 system guidelines and an electrode cap from Quik-Cap, Neuroscan, Compumedics, NC (Amplifier uses a Synamps 2 by Compumedics Neuroscan). All electrodes sites were employed in quantitative analysis. All EEG channels were referenced to linked electrodes placed on the left and right mastoid processes. Vertical and horizontal eye movements were monitored with bipolar recordings above and below the left eye and at the lateral aspect of the left and right eyes respectively. All channels were amplified, low-pass filtered (50 Hz), digitized at a rate of 500 Hz (Neuroscan, Compumedics, NC) and impedance was below 50 Ω . All post-processing of the error related negativity (ERN) and N2 data were performed using Curry® (Neuroscan, Compumedics, NC). Power spectral analysis was performed in MATLAB and all EEG channels were analyzed. For ERN and N2, measurements included F2 (midline frontal), FCZ (midline fronto-central), and CZ (midline central).







Fig. 2: Experimental procedure.

Results:

TABLE 1: RESULTS PRE- VS POST-NI-PBS

ANXIETY QUESTIONNAIRES	PRE	POST	V OR T (P)	P
GAD-7	14.90 ± 0.83	7.87 ± 0.80	V = 475.6	<0.001***
STAI-S	49.80 ± 1.94	42.16 ± 2.15	(33) = 2.85	0.000**
STAI-T	54.25 ± 1.76	53.03 ± 1.67	(33) = 0.94	0.35
Flanker ERPs (μV)				
ERN amplitude	-5.29 ± 0.38	-11.86 ± 1.08	V = 459	<0.001***
ERN latency	43.12 ± 3.87	35.38 ± 2.61	(33) = 1.05	0.30
N2 amplitude	-0.67 ± 0.27	-3.36 ± 0.30	(33) = 7.14	<0.001***
N2 latency	272.75 ± 6.44	276.25 ± 6.51	(33) = 0.46	0.65
Absolute Power Spectral Density (10log [dB] (μV ² /Hz))				
Theta (fronto-central)	5.75 ± 0.61	6.16 ± 0.63	V = 155	0.04*
High beta (posterior)	0.65 ± 0.10	0.94 ± 0.10	V = 141	0.02*
Relative Power Spectral Density (10log [dB] (μV ² /Hz))				
High beta (posterior)	0.63 ± 0.00	0.04 ± 0.00	V = 131	0.01*
Resting Mean Physiological Measures				
SCL (μS)	1.45 ± 0.24	2.32 ± 0.46	V = 91	<0.001***
HR (bpm)	74.89 ± 1.36	73.32 ± 1.42	(33) = 1.68	0.10
HRV (RMSSD)	41.48 ± 2.54	43.54 ± 2.32	(36) = -1.20	0.24
HRV (pRMSSD)	18.61 ± 2.26	21.34 ± 2.05	(36) = -1.92	0.32



Discussion:

- Similar to past findings, high beta increased after a single NI-PBS session³.
- Increased theta power post-NI-PBS may indicate an enhanced state of relaxation and has been shown to increase during meditation⁴.
- Increased ERP amplitudes and beta power may indicate potential cognitive enhancement post-NI-PBS⁵.
- Greater ERNs have also been associated with decreased perceived stress after walking in nature⁶ and more broadly in meditation⁷.
- Similar to Fauser et al.'s (2012) findings, an increase in ERN amplitude and frontocentral theta power may reflect a downregulation of the DMN post-NI-PBS⁸.

Conclusion:

- A single 30-minute session of NI-PBS reduced perceived anxiety and enhanced cognitive ERPs and brain oscillations associated with deep relaxation (theta) and focused attention (beta). Other physiological measures (e.g., skin conductance) were not modulated as expected.
- Future work should further assess potential physiological changes associated with anxiety as well as potential cognitive effects induced by longitudinal NI-PBS treatment.

References:

- World Health Organization (WHO). (2024, Aug 15). Mental Disorders. <https://www.who.int/news-room/fact-sheets/detail/mental-disorders>
- Santorum et al. (2023). Global prevalence and burden of depressive and anxiety disorders in 2004 countries and territories in 2020 due to the COVID-19 pandemic. *The Lancet*, 398(10312), 1700-1712.
- Ching et al. (2022). Efficacy and tolerability of cranial electrotherapy stimulation in the treatment of anxiety: a systematic review and meta-analysis. *Front Psychiatry*, 13, 899040.
- Bjornbly et al. (2008). A pilot study of cranial electrotherapy stimulation for generalized anxiety disorder. *Journal of Clinical Psychiatry*, 69(3), 412-417.
- Kirsch et al. (2014). Military service member and veteran self-reports of efficacy of cranial electrotherapy stimulation for anxiety, posttraumatic stress disorder, insomnia, and depression. *US Army Medical Department Journal*, Oct-Dec, 46-54.
- Fauser et al. (2012). Effects of cranial electrotherapy stimulation on resting state brain activity. *Brain and Behavior*, 2(3), 211-220.
- Kim et al. (2021). Effects of cranial electrotherapy stimulation with novel in-ear electrodes on anxiety and resting-state brain activity: A randomized double-blind placebo-controlled trial. *Journal of Affective Disorders*, 295, 855-864.
- Lange & Guggen (2018). Prospective study of brain wave changes associated with cranial electrotherapy stimulation. *Primary Care Companion for CNS Disorders*, 20(1), 267-14.
- Deloukas et al. (2016). Electroencephalographic Correlates of States of Concentrative Meditation. *Int J Psychophysiol*, 110, 27-39.
- Ahany et al. (2016). Introduction to EEG and Speech-Based Emotion Recognition. Amsterdam: Academic Press.
- Lo Tempio et al. (2020). Nature as a potential modulator of the error-related negativity: a registered report. *Int J Psychophysiol*, 156, 49-59.
- Andrew et al. (2017). Behavioral and electrophysiological evidence of enhanced performance monitoring in meditators. *Mindfulness*, 8(8), 1603-1614.
- Buckner et al. (2009). The brain's default network: anatomy, function, and relevance to disease. *Ann NY Acad Sci*, 1156(1), 1-38.
- Schneiders et al. (2008). Frontal theta EEG activity correlates negatively with the default mode network in resting state. *Int J Psychophysiol*, 67(3), 242-251.

Acknowledgements:

This study was funded by MITACS and Rogee Life Canada Inc. Rogee is an early stage start-up developing neurotech wearables for the treatment of anxiety. Rogee is supported by the Ontario Brain Institute, the Centre for Aging + Brain Health Innovation, Velocity, and BVZ.

QR CODE TO DIGITAL POSTER

